menu
    • menu
    [{"orgOrder":0,"company":"Vyluma","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Laboratoires Thea","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Laboratoires Thea"},{"orgOrder":0,"company":"Vyluma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Inapplicable"},{"orgOrder":0,"company":"Vyluma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Inapplicable"},{"orgOrder":0,"company":"Vyluma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Inapplicable"},{"orgOrder":0,"company":"Vyluma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Inapplicable"},{"orgOrder":0,"company":"Vyluma","sponsor":"Laboratoires Thea","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Laboratoires Thea","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Laboratoires Thea"},{"orgOrder":0,"company":"Vyluma","sponsor":"Nevakar","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Nevakar","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Nevakar"},{"orgOrder":0,"company":"Vyluma","sponsor":"Nevakar","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Nevakar","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Nevakar"},{"orgOrder":0,"company":"Vyluma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"mAChRs","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Vyluma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Vyluma

    Menu

    Vyluma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    China Accepts NVK002 Drug Application for Myopia Treatment

    Details : NVK002 (low-dose atropine) is a mAChR inhibitor small molecule drug, being evaluated as a potential treatment for myopia progression in children.

    Product Name : NVK002

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    January 29, 2025

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Vyluma Meets FDA on Atropine Solution for Pediatric Myopia

    Details : NVK002 (atropine sulfate) is a muscarinic M1/M2/M3 receptor antagonist. It is being evaluated for the treatment of pediatric myopia.

    Product Name : NVK002

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    June 18, 2024

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Vyluma Announces Positive Results From Second Stage of Phase III CHAMP Study of NVK002 for the Treatment of My...

    Details : NVK002 (atropine) inhibits the muscarinic actions of acetylcholine, which is investigated for anti-allergy and dry eye syndrome and progressive myopia.

    Product Name : NVK002

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    November 10, 2023

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Study Phase : Phase III

    Sponsor : Nevakar

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Vyluma Announces FDA Acceptance of New Drug Application for NVK002, Its Novel Investigational Treatment for Pe...

    Details : NVK002 (atropine) is an investigational, preservative-free, low-dose atropine eye drop, using Vyluma’s proprietary technology to address stability, tolerability, and safety and developed for the treatment of Pediatric Myopia.

    Product Name : NVK002

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    June 06, 2023

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Sponsor : Nevakar

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Study Phase : Phase III

    Sponsor : Laboratoires Thea

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Vyluma Announces Positive Results From Phase III CHAMP Study of NVK002 for Treatment of Myopia Progression in ...

    Details : NVK002 (atropine) is a proprietary, investigational, low-dose, preservative-free atropine eye drop administered nightly as a potential treatment for the progression of myopia in children.

    Product Name : NVK002

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    October 27, 2022

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Sponsor : Laboratoires Thea

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Study Phase : Phase III

    Sponsor : Laboratoires Thea

    Deal Size : $150.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Vyluma and Laboratoires Thea Enter into Licensing Agreement for the Registration and Commercialization of NVK0...

    Details : The agreement represents an expansion of the previously announced exclusive licensing agreement for the commercialization of NVK002 (having Atropine) in Europe and other select countries.

    Product Name : NVK002

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    June 14, 2022

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Sponsor : Laboratoires Thea

    Deal Size : $150.0 million

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Study Phase : Phase III

    Sponsor : Nevakar

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Vyluma Completes Last Patient Visit for Primary Analysis of Pivotal Phase III CHAMP Study Evaluating NVK002 fo...

    Details : NVK002 (atropine) is a proprietary, investigational, preservative-free eye drop administered nightly, which, if approved, would be the first-in-class pharmaceutical treatment for myopia progression in children.

    Product Name : NVK002

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    January 09, 2022

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Sponsor : Nevakar

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Vyluma Inc Launches With Robust Ophthalmic Portfolio, Leading With a Pharmaceutical Treatment In Phase III for...

    Details : NVK002 (atropine) inhibits the muscarinic actions of acetylcholine, which is investigated for anti-allergy and dry eye syndrome and Myopia, Progressive.

    Product Name : NVK002

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    May 25, 2021

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed

    Vyluma

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    First Patient Completes Three Year Enrollment In Nevakar’S Phase III Champ Study of NVK002 Evaluating Low-Do...

    Details : NVK002 (atropine) inhibits the muscarinic actions of acetylcholine, which is investigated for anti-allergy and dry eye syndrome and Myopia, Progressive.

    Product Name : NVK002

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    September 11, 2020

    Lead Product(s) : Atropine Sulfate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth